Last reviewed · How we verify

efgartigimod administration — Competitive Intelligence Brief

efgartigimod administration (efgartigimod administration) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Autoimmune diseases.

phase 3 Monoclonal antibody FcRn Autoimmune diseases Small molecule Live · refreshed every 30 min

Target snapshot

efgartigimod administration (efgartigimod administration) — Clinique Neuro-Outaouais. Efgartigimod is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn) to reduce immunoglobulin G (IgG) levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
efgartigimod administration TARGET efgartigimod administration Clinique Neuro-Outaouais phase 3 Monoclonal antibody FcRn
Vyvgart EFGARTIGIMOD ALFA Argenx Bv marketed Endoglycosidase [EPC] IgG receptor FcRn large subunit p51 2021-01-01
UPLIZNA UPLIZNA Amgen marketed FcRn antagonist FcRn (neonatal Fc receptor)
Efgartigimod Efgartigimod M. Peter Marinkovich marketed Endoglycosidase [EPC] FcRn
Efgartigimod PH20 SC Efgartigimod PH20 SC argenx marketed FcRn antagonist Neonatal Fc receptor (FcRn)
IV efgartigimod IV efgartigimod Rambam Health Care Campus marketed FcRn inhibitor Neonatal Fc receptor (FcRn)
RYSTIGGO ROZANOLIXIZUMAB-NOLI UCB INC marketed Neonatal Fc Receptor Blocker [EPC] IgG receptor FcRn large subunit p51

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

  1. Pfizer · 7 drugs in this class
  2. argenx · 7 drugs in this class
  3. Johnson & Johnson · 2 drugs in this class
  4. German CLL Study Group · 2 drugs in this class
  5. Amgen · 2 drugs in this class
  6. Hoffmann-La Roche · 2 drugs in this class
  7. Brii Biosciences Limited · 2 drugs in this class
  8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
  9. Biotest · 2 drugs in this class
  10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). efgartigimod administration — Competitive Intelligence Brief. https://druglandscape.com/ci/efgartigimod-administration. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: